Aurobindo Pharma said its wholly-owned arm, CuraTeQ Biologics, plans to invest around Rs 300 crore in capacity expansion of biologics manufacturing facilities

The board of directors of CuraTeQ Biologics approved the expansion of its operations by establishing another mammalian cell culture manufacturing facility of higher capacity to cater to future requirements, Aurobindo Pharma said in a regulatory filing.

"The capital expenditure for ramping up capacities is estimated to be around Rs 300 crore," it said, adding that the facility is likely to be fully operational by FY26.

Further, the board also approved entering into contract manufacturing operations (CMO) for biologicals for effective utilisation of capacities.

This would augment the business prospects in this area as the global biologics contract manufacturing demand is growing at 8-10 per cent and CuraTeQ will actively seek customers in the CMO area, it added.

The company further said the board of its other wholly-owned subsidiary, Auro Vaccines Pvt Ltd, has also approved exploring possibilities to offer contract manufacturing services to global vaccine developers to effectively utilise its existing manufacturing capacity.

Auro Vaccines is engaged in the business of developing and manufacturing vaccines biologicals.